| |||||||||
Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Generation F?+1N1p Donating Investigator David Ginsburg, University of Michigan Description
Mice that are homozygous for the targeted mutation are viable, normal in size and do not display any gross physical or behavioral abnormalities. No gene product (protein) was immunodetected. Serum from mutant mice has no plasma plasminogen activator inhibitor 1 (PAI-1) binding capacity and can not support cell spreading on tissue culture plastic surface. Thrombosis rate after arterial injury is enhanced and angiogenesis in response to tissue injury is decreased in mutant mice. This mutant mouse strain represents a model that may be useful in studies of the in vivo function of vitronectin.Development
A targeting vector containing neomycin resistance and herpes simplex virus thymidine kinase genes was used to disrupt all of the coding sequence of the targeted gene and approximately 3 kb of downstream sequence. The construct was electroporated into 129S2/SvPas derived D3 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6J blastocysts. The resulting chimeric male mice were crossed to B6D2F1/J female mice, and then backcrossed to C57BL/6J for 12 generations before being made homozygous.
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Congenic Nomenclature
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
Vtntm1Dgi/Vtntm1Dgi
B6.129S2-Vtntm1Dgi
- homeostasis/metabolism phenotype
- abnormal blood coagulation (MGI Ref ID J:134443)
- in a model of ferric chloride induced vessel injury, mutants exhibit unstable thrombi and a greater number of emboli
- in a cremaster muscle arteriole mode where vessel injury is induced by a nitrogen dye laser, mutants exhibit fewer platelets, lower fibrin content, and unstable fibrin within the thrombi compared to wild-type
- abnormal platelet physiology (MGI Ref ID J:134443)
- early platelet adhesion is not affected, however the second wave of thrombin-induced aggregation of gel-filtered platelets is abolished at a low concentration of thrombin
- mutant platelet-rich plasma shows a 32% increase in adenosine diphosphate-induced platelet aggregation in vitro compared to wild-type
- whole blood of mutants exhibits an increase in shear-induced platelet aggregation
- abnormal response to injury (MGI Ref ID J:134443)
- in a model of ferric chloride induced vessel injury, mutants exhibit unstable thrombi and a greater number of emboli
- vessel occlusion is delayed and frequent vessel re-opening occurs in mutants where vessel injury was induced with ferric chloride
- in a cremaster muscle arteriole mode where vessel injury is induced by a nitrogen dye laser, mutants exhibit fewer platelets, lower fibrin content, and unstable fibrin within the thrombi compared to wild-type
- hematopoietic system phenotype
- abnormal platelet physiology (MGI Ref ID J:134443)
- early platelet adhesion is not affected, however the second wave of thrombin-induced aggregation of gel-filtered platelets is abolished at a low concentration of thrombin
- mutant platelet-rich plasma shows a 32% increase in adenosine diphosphate-induced platelet aggregation in vitro compared to wild-type
- whole blood of mutants exhibits an increase in shear-induced platelet aggregation
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Vtntm1Dgi/Vtntm1Dgi
involves: 129S2/SvPas * C57BL/6 * DBA/2J
- normal phenotype
- no abnormal phenotype detected (MGI Ref ID J:30296)
- viable and fertile with no differences in blood counts or autopsy findings; histological analysis did not detect any abnormalities in the nervous system, heart, lung, liver and kidney
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:Vtntm1Dgi related
Cardiovascular Research
Vascular Defects (Thrombosis)
| Allele Symbol | Vtntm1Dgi | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, David Ginsburg | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | VN-; | ||
| Mutation Made By | XianXian Zheng, University of Michigan | ||
| Strain of Origin | 129S2/SvPas | ||
| ES Cell Line Name | D3 | ||
| ES Cell Line Strain | 129S2/SvPas | ||
| Gene Symbol and Name | Vtn, vitronectin | ||
| Chromosome | 11 | ||
| Gene Common Name(s) | AI256434; Aa1018; MGC124961; V75; VN; VNT; expressed sequence AI256434; | ||
| Molecular Note | A PGK-neomycin cassette replaced all eight exons. Western blot analysis did not detect protein in plasma of homozygous mutant mice, and cell adhesion experiments with sera derived from homozygous mice demonstrated that serum spreading activity was absent. [MGI Ref ID J:30296] | ||
Genotyping Protocols
Vtntm1Dgi, STD PCR, vers. 2
Helpful Links
Optimizing PCR Protocols
Zheng X; Saunders TL; Camper SA; Samuelson LC; Ginsburg D. 1995. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci U S A 92(26):12426-30. [PubMed: 8618914] [MGI Ref ID J:30296]
Fay WP; Parker AC; Ansari MN; Zheng X; Ginsburg D. 1999. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 93(6):1825-30. [PubMed: 10068653] [MGI Ref ID J:53442]
Liaw L; Birk DE; Ballas CB; Whitsitt JS; Davidson JM; Hogan BL. 1998. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 101(7):1468-78. [PubMed: 9525990] [MGI Ref ID J:46863]
Vtntm1Dgi relatedAkerman ME; Pilch J; Peters D; Ruoslahti E. 2005. Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. Proc Natl Acad Sci U S A 102(6):2040-5. [PubMed: 15687502] [MGI Ref ID J:96503]
Koschnick S; Konstantinides S; Schafer K; Crain K; Loskutoff DJ. 2005. Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin. J Thromb Haemost 3(10):2290-5. [PubMed: 16194205] [MGI Ref ID J:114352]
Lazar MH; Christensen PJ; Du M; Yu B; Subbotina NM; Hanson KE; Hansen JM; White ES; Simon RH; Sisson TH. 2004. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol 31(6):672-8. [PubMed: 15308506] [MGI Ref ID J:104660]
Reheman A; Gross P; Yang H; Chen P; Allen D; Leytin V; Freedman J; Ni H. 2005. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost 3(5):875-83. [PubMed: 15733060] [MGI Ref ID J:134443]
Wei C; Moller CC; Altintas MM; Li J; Schwarz K; Zacchigna S; Xie L; Henger A; Schmid H; Rastaldi MP; Cowan P; Kretzler M; Parrilla R; Bendayan M; Gupta V; Nikolic B; Kalluri R; Carmeliet P; Mundel P; Reiser J. 2008. Modification of kidney barrier function by the urokinase receptor. Nat Med 14(1):55-63. [PubMed: 18084301] [MGI Ref ID J:130835]
Colony Maintenance
Breeding & Husbandry This strain originated on a B6;129 background, was crossed once to B6D2F1/J before being backcrossed for 12 generations on the C57BL/6J background and is maintained as a homozygote.
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00 Cryopreserved Embryos Fee $1600.00
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00 Cryopreserved Embryos Fee $2080.00
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.